Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO(TM) (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020 - The Trentonian

Submitted by Anonymous (not verified) on Fri, 08/28/2020 - 15:31

Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO(TM) (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020 The Trentonian

Log in to post comments